Scholarlink

Purpose <p>The Exime prostatic stent, a silicone-based device designed for temporary urinary retention management, offers an alternative to indwelling urethral catheters (IUCs), allowing spontaneous voiding. This study aimed to compare the efficacy and safety of the Exime device with IUCs in patients with urinary retention due to benign prostatic obstruction (BPO).</p> Methods <p>This retrospective study included 43 patients from 2020 to 2024 with failed trial without catheter (TWOC) following acute urinary retention (AUR) secondary to BPO, prostate volume ≤ 120 mL, and intravesical prostatic protrusion &lt; 5&#xa0;mm. The stent was inserted under local anesthesia as an outpatient procedure. Primary endpoint: effectiveness in restoring urinary flow. Secondary endpoints: complications, patient preferences, and comparisons with IUCs.</p> Results <p>Median patient age was 86 years (IQR 78–90); median prostate volume was 45 mL (IQR 40–61). The stent was successfully inserted in 42 patients (98%), with all achieving spontaneous voiding. Median post-void residual volume was 45 mL (IQR 38–73), and 70% retained the stent for ≥ 4 weeks. Complications included obstruction (14%), infection (9%), and migration (7%). Compared to IUCs, the Exime stent reduced symptomatic urinary tract infections (9% vs. 40%, <i>p</i> = 0.03), bladder spasms (16% vs. 84%, <i>p</i> &lt; 0.001), and urinary leakage (0% vs. 30%, <i>p</i> &lt; 0.001). Patients reported lower pain (VAS 2 vs. 8, <i>p</i> &lt; 0.001) and higher satisfaction (VAS 8 vs. 1, <i>p</i> &lt; 0.001).</p> Conclusion <p>The Exime stent effectively managed urinary retention with fewer complications and higher patient satisfaction compared to IUCs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exime prostatic stent in acute and chronic urinary retention

  • 期刊论文

  • 发表日期：

    2025年3月19日

查看全文
  • Thibaut Long Depaquit,
  • Michael Baboudjian,
  • Alessandro Uleri,
  • William Berchiche,
  • Frederic Arroua,
  • Arthur Peyrottes,
  • Christophe Eghazarian,
  • Marc Fourmarier

摘要

Purpose

The Exime prostatic stent, a silicone-based device designed for temporary urinary retention management, offers an alternative to indwelling urethral catheters (IUCs), allowing spontaneous voiding. This study aimed to compare the efficacy and safety of the Exime device with IUCs in patients with urinary retention due to benign prostatic obstruction (BPO).

Methods

This retrospective study included 43 patients from 2020 to 2024 with failed trial without catheter (TWOC) following acute urinary retention (AUR) secondary to BPO, prostate volume ≤ 120 mL, and intravesical prostatic protrusion < 5 mm. The stent was inserted under local anesthesia as an outpatient procedure. Primary endpoint: effectiveness in restoring urinary flow. Secondary endpoints: complications, patient preferences, and comparisons with IUCs.

Results

Median patient age was 86 years (IQR 78–90); median prostate volume was 45 mL (IQR 40–61). The stent was successfully inserted in 42 patients (98%), with all achieving spontaneous voiding. Median post-void residual volume was 45 mL (IQR 38–73), and 70% retained the stent for ≥ 4 weeks. Complications included obstruction (14%), infection (9%), and migration (7%). Compared to IUCs, the Exime stent reduced symptomatic urinary tract infections (9% vs. 40%, p = 0.03), bladder spasms (16% vs. 84%, p < 0.001), and urinary leakage (0% vs. 30%, p < 0.001). Patients reported lower pain (VAS 2 vs. 8, p < 0.001) and higher satisfaction (VAS 8 vs. 1, p < 0.001).

Conclusion

The Exime stent effectively managed urinary retention with fewer complications and higher patient satisfaction compared to IUCs.